Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.17
↓-63% vs avg
5yr avg: 3.13
30Y Low0.4·High9.8
ROE
↓
-49.5%
↓+6% vs avg
5yr avg: -52.8%
30Y Low-91%·High-43%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ZNTL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Zentalis Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $251M | $97M | $215M | $991M | $1.1B | $3.6B | $2.1B | — | — |
| Enterprise Value | $254M | $101M | $224M | $1.0B | $1.1B | $3.6B | $2.1B | — | — |
| P/E Ratio → | -1.84 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 3.19 | — | — | — | — | — | — |
| P/B Ratio | 1.17 | 0.45 | 0.64 | 2.27 | 2.45 | 9.85 | 6.39 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ZNTL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 3.32 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
ZNTL Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -49.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | -283.6% | — | — | — | — | — | -169878.6% |
| Net Profit Margin | — | — | -246.0% | — | — | — | — | — | -150478.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.5% | -49.5% | -42.8% | -67.1% | -59.3% | -45.5% | -58.7% | -90.7% | -65.2% |
| ROA | -38.1% | -38.1% | -33.4% | -52.4% | -46.2% | -37.9% | -51.9% | -70.7% | -51.4% |
| ROIC | -40.5% | -40.5% | -35.8% | -50.3% | -43.2% | -51.5% | -62.7% | -650.4% | -249.4% |
| ROCE | -48.5% | -48.5% | -43.9% | -60.5% | -49.1% | -56.6% | -57.9% | -86.6% | -68.4% |
ZNTL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($40M total debt minus $36M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.13 | 0.10 | 0.11 | 0.13 | 0.01 | 0.04 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | 0.03 | 0.04 | 0.01 | -0.04 | -0.16 | -0.95 | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -88.27 | — | — | — | — |
ZNTL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Zentalis Pharmaceuticals, Inc.'s current ratio of 6.93x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.16x to 6.93x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Quick Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Cash Ratio | 6.73 | 6.73 | 7.04 | 6.96 | 7.72 | 7.74 | 11.84 | 4.51 | 4.05 |
| Asset Turnover | — | — | 0.16 | — | — | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 27.07 | — | — | — | — | — | 23907.50 |
ZNTL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Zentalis Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $72M | $71M | $65M | $53M | $43M | $41M | $36M | $18M |
Peer Comparison
Compare ZNTL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ZNTLYou | $251M | -1.8 | — | — | — | — | -49.5% | -40.5% | — |
 RVMD | $32B | -25.1 | — | — | — | — | -58.1% | -54.3% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 AUPH | $2B | 7.7 | 17.8 | 15.1 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 TGTX | $7B | 17.3 | 61.0 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARVN | $457M | -5.5 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 PTGX | $7B | -53.6 | — | 125.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 MGNX | $255M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
What if you invested $1,000 in ZNTL 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ZNTL be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ZNTL Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationZNTL vs RVMD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Revolution Medicines, Inc..
Compare NowZNTL — Frequently Asked Questions
Quick answers to the most common questions about buying ZNTL stock.
What is Zentalis Pharmaceuticals, Inc.'s P/E ratio?
Zentalis Pharmaceuticals, Inc.'s current P/E ratio is -1.8x. This places it at the 50th percentile of its historical range.
What is Zentalis Pharmaceuticals, Inc.'s ROE?
Zentalis Pharmaceuticals, Inc.'s return on equity (ROE) is -49.5%. The historical average is -59.8%.
Is ZNTL stock overvalued?
Based on historical data, Zentalis Pharmaceuticals, Inc. is trading at a P/E of -1.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.